Mitsubishi UFJ Asset Management Co. Ltd. Has $2.19 Million Holdings in Bruker Co. (NASDAQ:BRKR)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 38.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 36,628 shares of the medical research company's stock after acquiring an additional 10,206 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.'s holdings in Bruker were worth $2,188,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. KLP Kapitalforvaltning AS bought a new position in shares of Bruker during the 4th quarter valued at $1,260,000. Sei Investments Co. increased its position in Bruker by 21.8% during the fourth quarter. Sei Investments Co. now owns 62,006 shares of the medical research company's stock worth $3,635,000 after buying an additional 11,087 shares during the last quarter. American Century Companies Inc. raised its holdings in Bruker by 1.2% during the fourth quarter. American Century Companies Inc. now owns 28,971 shares of the medical research company's stock valued at $1,698,000 after buying an additional 341 shares in the last quarter. Xponance Inc. lifted its position in shares of Bruker by 2.7% in the fourth quarter. Xponance Inc. now owns 21,931 shares of the medical research company's stock worth $1,286,000 after buying an additional 569 shares during the last quarter. Finally, Natixis Advisors LLC boosted its stake in shares of Bruker by 145.8% during the 4th quarter. Natixis Advisors LLC now owns 360,631 shares of the medical research company's stock worth $21,140,000 after acquiring an additional 213,937 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Bruker Stock Performance

Shares of BRKR traded down $1.20 on Friday, reaching $36.46. 4,101,408 shares of the stock traded hands, compared to its average volume of 1,402,128. The firm has a market cap of $5.53 billion, a price-to-earnings ratio of 47.97, a P/E/G ratio of 2.16 and a beta of 1.18. Bruker Co. has a 12 month low of $34.10 and a 12 month high of $91.34. The stock's 50-day moving average price is $48.64 and its 200-day moving average price is $56.00. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Equities analysts forecast that Bruker Co. will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.55%. Bruker's dividend payout ratio is currently 26.32%.

Analysts Set New Price Targets

BRKR has been the topic of a number of recent analyst reports. Bank of America raised their price objective on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Barclays dropped their price target on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a research report on Monday, February 10th. Stifel Nicolaus decreased their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, UBS Group assumed coverage on shares of Bruker in a report on Tuesday, December 10th. They set a "neutral" rating and a $66.00 price target for the company. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Bruker presently has a consensus rating of "Moderate Buy" and an average price target of $70.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.